Dermal Filler Global Market Report 2023 – By Filler Type (Calcium Hydroxylapatite, Hyaluronic Acid, Poly Alkylimide, Polylactic acid, Polymethylmethacrylate Microspheres), By Product (Biodegradable, Non Biodegradable), By Application (Scar Treatment, Wrinkle Correction Treatment, Lip Enhancement, Restoration Of Volume or Fullness), By End User (Hospital, Cosmetic Clinics, Outpatient Centres, Beauty Centres, Other End Users) – Market Size, Trends, And Global Forecast 2023-2032

Hyaluronic acid-based dermal fillers refer to a form of dermal filler that is only used for a short period of time. Hyaluronic acid attracts water to the skin, making it more moisturized. It is used to treat shallow and fine wrinkles with Belotero and Restyling Silk, which prevents skin from aging. The main types of hyaluronic acid-based dermal fillers are single-phase products, and duplex products. Single-phase products are widely employed for a variety of skin-related applications to address abnormalities in the soft face tissues since the uncross-linked HA increases elastin and collagen production, making the skin appear more youthful and healthier. They are used in specialty and dermatology clinics, hospitals and clinics for various applications such as wrinkle removal, lip augmentation, rhinoplasty, and other applications. The global hyaluronic acid based dermal fillers market is segmented - 1) By Product: Single-Phase Product, Duplex Product 2) By Usage: Speciality And Dermatology Clinics, Hospitals And Clinics 3) By Application: Wrinkle Removal, Lip Augmentation, Rhinoplasty, Other Applications The global hyaluronic acid-based dermal fillers market size grew from $3.97 billion in 2022 to $4.44 billion in 2023 at a compound annual growth rate (CAGR) of 11.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the hyaluronic acid-based dermal fillers market is expected to grow to $6.65 billion in 2027 at a CAGR of 10.6%. Increasing demand for non-invasive dermatology techniques is driving the growth of hyaluronic acid-based dermal fillers. Deep palpation, x-rays, and blood pressure checks are examples of non-invasive tests that require breaking the skin or entering the body. Most of the treatments are non-invasive and are done by using acid-based dermal fillers as they have minimal risks involved and give long-lasting results. For instance, in February 2022, The American Society of Plastic Surgeons (ASPS), a society for American plastic surgeons, said that every year more than 17 million adults opt for cosmetic surgeries that consist of minimally invasive options such as body contouring, lasers, and injections. This demand is expected to drive the hyaluronic acid-based dermal fillers market. Major players in the hyaluronic acid-based dermal fillers market are Bohus Biotech AB, Allergan, Galderma Laboratories L.P., Merz Pharmaceuticals, Genzyme Corporation, Anika Therapeutics Inc., LG Life Sciences, Bio Plus Co. Ltd., Sculpt Luxury Dermal Fillers Ltd., Bioxis Pharmaceutical, Sinclair Pharma, Laboratories Vivacy, Medicis Aesthetics Holdings, Inc., and Inamed Corp. Technological advancements are shaping the hyaluronic acid-based dermal fillers market. Major companies operating in the hyaluronic acid-based dermal fillers sector are focused on developing new technological solutions to strengthen their position in the hyaluronic acid-based dermal fillers. For instance, in 2021, a new treatment called laser resurfacing treatments was introduced in the market which is more efficient and less invasive, addressing multiple skin concerns. It uses lasers to solve all the skin problems at once making them more appealing. Moreover, the treatment can also be used to cope with the COVID-19 stress. In October 2020 Allergan Aesthetics, an U.S-based manufacturer of drugs and medical devices in the areas of medical aesthetics, eye care, central nervous system acquired Luminera Dermal Filler for an undisclosed amount. Through this acquisition, Allergan Aesthetics will acquire Luminera's entire dermal filler portfolio as well as its RandD pipeline, complementing Allergan Aesthetics' leading dermal filler portfolio with its JUVÉDERM® filler collection. Luminera is a manufacturer and an R and D company for injectable medical devices in the aesthetic medicine field. North America was the largest region in the hyaluronic acid-based dermal fillers market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in hyaluronic acid-based dermal fillers market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the hyaluronic acid-based dermal fillers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The hyaluronic acid-based dermal fillers market consists of sales of fat grafting, permanent soft tissue filler, poly-l-lactic acid, calcium hydroxylapatite, and hyaluronic acid. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The hyaluronic acid-based dermal fillers market research report is one of a series of new reports from The Business Research Company that provides hyaluronic acid-based dermal fillers market statistics, including hyaluronic acid-based dermal fillers industry global market size, regional shares, competitors with a hyaluronic acid-based dermal fillers market share, detailed hyaluronic acid-based dermal fillers market segments, market trends and opportunities, and any further data you may need to thrive in the hyaluronic acid-based dermal fillers industry. This hyaluronic acid-based dermal fillers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Anti-aging refers to a term used to describe substances meant to slow down or stop the ageing process. It is described as a method for halting, delaying, or reversing the ageing process in humans. The main types of products in anti-aging are UV absorbers, anti-wrinkle products, dermal fillers, Botox, and anti-stretch mark products. The UV absorbers are used to disperse ultraviolet light into a lower energy state. These are commonly used to protect polymers by blocking UV light from damaging the polymer. The different treatments include hair restoration, adult acne therapy, breast augmentation, liposuction, chemical peels, and others and involve various demographics such as generation X, baby boomers, generation Y, and generation Z. It is used in anti-wrinkle treatment, anti-pigmentation, skin resurfacing, and other applications and is implemented in several sectors, including hospitals, clinics, and home healthcare. The global anti aging market is segmented - 1) By Product Type: UV Absorbers, Anti-Wrinkle Products, Dermal Fillers, Botox, Anti-Stretch Mark Products 2) By Treatment: Hair Restoration, Adult Acne Therapy, Breast Augmentation, Liposuction, Chemical Peel, Other Treatments 3) By Demographic: Generation X, Baby Boomers, Generation Y, Generation Z 4) By Application: Anti-Wrinkle Treatment, Anti-Pigmentation, Skin Resurfacing, Other Applications 5) By End-User: Hospitals, Clinics, Home Healthcare The global anti aging market size will grow from $50.1 billion in 2022 to $54.5 billion in 2023 at a compound annual growth rate (CAGR) of 8.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the anti aging is expected to grow to $72.06 billion in 2027 at a CAGR of 7.2%. The increase in demand for cosmetic products is significantly driving the growth of the anti aging market. Anti-aging cosmetics are a subset of cosmetics that focus on reducing the effects of ageing and wrinkles on the human skin. The use of these cosmetics in treatments or post-treatments enhances the results of anti-aging surgery. For instance, according to Cosmetics Europe, a European trade association for cosmetics, the cosmetics and personal care industry contribute at least €29 billion (USD 33.14 billion) to the European economy each year, and the number of people who use cosmetics is rapidly increasing, with the number of people using cosmetics in Europe exceeding 500 million by 2020. Hence, the growing demand for cosmetic products is expected to propel the growth of the anti aging market going forward. Major players in the anti aging market are Allergan plc, L'Oréal S.A., Beiersdorf, The Estée Lauder Companies Inc., The Procter & Gamble Company, Shiseido Cosmetics., Unilever PLC, Lumenis, Home Skinovations Ltd., Nu Skin Enterprises Inc., Galderma SA, Koninklijke Philips NV, Alma Lasers, PhotoMedex, Candela Corporation, Hologic Inc., Pierre Fabre S.A., and Galderma SA. Technology advancements are shaping the anti aging market. Major companies operating in the anti-aging sector are focused on developing new technological solutions to meet consumer demand and strengthen their position. For instance, in March 2021, Laboratoires Pierre Fabre, a France based pharmaceutical and cosmetics company, launched the TRIASORB sun protection product based on its patented technology. TRIASORB is the first organic filter having a special capacity to absorb and reflect damaging sun radiation, such as UVB, short UVA, and long UVA rays, as well as intense visible blue light. In September 2020, Grifols, S.A., a Spain-based pharmaceutical and chemical manufacturer, acquired Alkahest, Inc., for $146 million. Through this acquisition, Grifols will increase its discovery research and development based on knowledge of the human plasma proteome to find novel treatments for age-related disorders. Grifols and Alkahest will be able to develop new plasma proteins, new uses for presently licensed plasma proteins, biomarkers for diagnostics, recombinant proteins and antibodies, as well as small-molecule medications, thanks to this special proteomic platform of targets. Alkahest is a US-based clinical stage biopharmaceutical company committed to fully comprehending the human plasma proteome and specializing in plasma proteins and their recombinant equivalents that have been identified as potential medicinal drugs. North America was the largest region in the anti aging market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anti aging market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the anti aging market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The anti aging market consists of sales of topical agents, antioxidants Cell regulators, and invasive procedures. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The anti aging market research report is one of a series of new reports from The Business Research Company that provides anti aging market statistics, including anti aging industry global market size, regional shares, competitors with an anti aging market share, detailed anti aging market segments, market trends and opportunities, and any further data you may need to thrive in the anti aging industry. This anti aging market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Dermatology medical lasers are used in the treatment of medical conditions related to the skin and for the removal of tattoos, wrinkles and scars. The main devices of dermatology medical lasers are surgical lasers and vascular lasers. Vascular laser is a type of device that is utilized to treat vascular lesions, like port wine stains, spider veins, rosacea, and wrinkles by targeting the vessels in these specific areas. The various applications involved are cancer, hair removal, tattoo removal, resurfacing, and others that are used by various end-users such as hospitals, skincare clinics, and cosmetic surgical centers. The global dermatology medical lasers market is segmented - 1) By Device: Surgical Lasers, Vascular Lasers 2) By End-users: Hospitals, Skin Care Clinics, Cosmetic Surgical Centres 3) By Application: Cancer, Hair Removal, Tattoo Removal, Resurfacing, Other Applications The global dermatology medical lasers market size grew from $3.04 billion in 2022 to $3.59 billion in 2023 at a compound annual growth rate (CAGR) of 17.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global dermatology medical lasers is expected to grow from $6.76 billion in 2027 at a CAGR of 17.2%. The growing demand for cosmetic procedures is expected to drive the dermatology medical lasers market. There has been an increase in the number of people opting for cosmetic procedures to enhance the appearance levels and treatment of defects on the skin. According to the American Society of Plastic Surgeons data, $16.7 billion was spent on cosmetic procedures in the U.S. in 2020. The poll also revealed that 11% of women surveyed said they are more interested in cosmetic plastic surgery or non-surgical procedures than before COVID-19. Dermatology lasers are used in cosmetic procedures such as removal of fine lines, wrinkles, skin tightening, pigmented lesions, precancerous lesions, vascular lesions, tattoos, hair removal, acne scars, and others. Hence, the growing demand for cosmetic procedures among users aids in the growth of the dermatology medical lasers market. Major players in the dermatology medical lasers market are Cynosure, Peninsula, Miracle Laser, Syneron, Shenzhen GSD, Sincoheren, Fotona, Alma Lasers Ltd., and Cutera. Alternatives for laser skin treatment are expected to hinder the dermatology medical lasers market. The growing popularity of alternative methods of skin treatment such as the use of drugs, chemical treatment, microneedle, and Botox surgery is expected to hinder the growth of the market. For instance, according to the American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS), the demand for surgical and nonsurgical facial plastic surgery treatments increased by 40% as compared to 2020. Thus, the demand for alternatives is expected to restrain the growth. Companies are increasingly investing in Picosecond Lasers for skin treatments other than tattoo removal as they have found their use in the treatment of acne, skin lightening, and skin tightening. For instance, in January 2021, LASEROPTEK Co Ltd received FDA 510(k) clearance for its next-generation PicoLO Premium™ Picosecond ND: YAG Laser. Therefore, the use of picosecond lasers in dermatological processes is expected to be the new trend in the dermatology medical lasers market. In March 2020, SemiNex Corporation, a U.S-based high-diode manufacturer, announced its collaboration with Dermal Photonics Corporation, a manufacturer of Nira skincare - a professional home laser technology. Through this collaboration, SemiNex Corporation plans to enhance home-based lasers for dermatology procedures. Dermal Photonics is a US-based medical device company. North America was the largest region in the dermatology medical lasers market in 2022. Asia-Pacific was the second largest region in the dermatology medical lasers market report. The regions covered in the dermatology medical lasers analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the dermatology medical lasers market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The dermatology medical lasers market consists of sales of surgical lasers and vascular lasers. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The dermatology medical lasers market research report is one of a series of new reports from The Business Research Company that provides dermatology medical lasers market statistics, including dermatology medical lasers industry global market size, regional shares, competitors with a dermatology medical lasers market share, detailed dermatology medical lasers market segments, market trends and opportunities, and any further data you may need to thrive in the dermatology medical lasers industry. This dermatology medical lasers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Dermatitis refer to the inhibitors that treat skin inflammation, which is characterised by itchy rashes on swollen and reddish skin, in the outer layer of the body. It is a general term that describes a common skin irritation. The main classes of drugs in dermatitis are corticosteroids, emollients/moisturizers, antihistamines, calcineurin inhibitors, antibiotics, immunomodulators, and interleukin inhibitors. Corticosteroids are a group of steroid hormones generated by vertebrates' adrenal cortex and are also synthetic equivalents of these hormones. The different routes of administration include topical, oral, and injectable and are used in cancer, blood disorders, chronic diseases, and infectious diseases. It is distributed through various channels such as hospitals, retail pharmacies, drug stores, and online or mail pharmacies. The global dermatitis market is segmented - 1) By Drug Class: Corticosteroids, Emollients/Moisturizers, Antihistamines, Calcineurin Inhibitors, Antibiotics, Immunomodulators, Interleukin Inhibitors 2) By Distribution Channel: Hospital, Retail Pharmacies, Drug Stores, Online Or Mail Pharmacies 3) By Route Of Application: Topical, Oral, Injectable 4) By Application: Cancer, Blood Disorders, Chronic Diseases, Infectious Diseases The global dermatitis market size will grow from $6.46 billion in 2022 to $6.89 billion in 2023 at a compound annual growth rate (CAGR) of 6.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global dermatitis is expected to grow to $8.57 billion in 2027 at a CAGR of 5.6%. Growth in the atopic dermatitis market is primarily driven by the increasing global prevalence of the disease. The prevalence of dermatitis in children is estimated to be around 15-20% while it is 1-3% in adults. The rising cases of food allergies are adding to the prevalence of dermatitis which ultimately leads to the increase in demand for medicines to cure this disease. For example, according to the allergy asthma network 2020, approximately 31.6 million people in the United States have some form of atopic dermatitis. The prevalence of atopic dermatitis globally in children have 15-20 percent and in adults have 1 to 3 percent. Major players in the dermatitis market are LEO Pharma A/S, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi S.A., Bayer HealthCare, Encore Dermatology Inc., Meda Pharmaceuticals, Allergan PLC. (Republic of Ireland) and Bristol-Myers Squibb. The strict government regulations are one of the restraints for the dermatitis market. Atopic Dermatitis (eczema) usually occurs at a very early stage (0-5 years). To find the efficacy and efficiency of the drug, it has to be tried on every type of patient. The effects of certain drugs in adults are quite different than in children, as a reasonable result of the clinical trial cannot be used for the production of drugs that will be served to the children. This hinders the research and requires more effort in clearing regulations set by FDA. For example, as the patient population is largely children, the FDA in its CFR Code Title 21, Part 50 Protection of Human Subjects, and subpart D has laid down guidelines for the additional safeguard for children in clinical investigation. The regulation complies with the Children’s Health Act of 2000 which requires all children subjected to clinical trials to be given additional protection. The dermatitis market has witnessed a trend of increasing mergers and acquisitions (M&As), done with the purpose of business expansion and increasing visibility. M&As are playing a significant role in today's world and are assumed to expand this market in the years to come. The vendors in this industry are focusing on collaboration and partnerships to expand their portfolios and improve their market presence. Companies are also strategically making M&As to reduce competition and increase the scalability of their businesses. For instance, in January 2020, Eli Lilly and Company, a US-based pharmaceutical company specializing in the discovery, development, manufacturing, and commercialization of human drugs, acquired Dermira, Inc. for an amount of $1.1 billion. Through this acquisition, Lebrikizumab, an innovative, experimental monoclonal antibody, has been added to the immunology pipeline and marketed dermatology medicines in the product portfolio of Eli Lilly for the treatment of moderate-to-severe atopic dermatitis in patients 12 years of age and older. Dermira, Inc. is a US-based biopharmaceutical company pioneering in the discovery and development of novel therapies for dermatology patients. The dermatitis market is governed by several regulatory bodies that require the drug manufacturers to get approvals from the concerned authorities before launching their medicines into the market. Two such major regulatory bodies are PMDA (Japan) and CDSCO (India) which carry out quality checks before declaring the drugs suitable for consumption. PMDA reviews the products to ensure the safety, quality, and efficacy of pharmaceuticals and then approves the products that are suitable in every parameter. Similarly, CDSCO is the central drug authority that is responsible for the approval of new drugs in India. These tedious approval processes make the drugs more effective and safe thereby having a positive impact on the dermatitis drugs market. North America was the largest region in the dermatitis market in 2022. Middle East is expected to be the fastest-growing region in the dermatitis market report during the forecast period. The regions covered in the dermatitis industry report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the dermatitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The dermatitis market consists of sales of Stasis dermatitis, atopic dermatitis, and irritant contact dermatitis. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The dermatitis market research report is one of a series of new reports from The Business Research Company that provides dermatitis market statistics, including dermatitis industry global market size, regional shares, competitors with a dermatitis market share, detailed dermatitis market segments, market trends, and opportunities, and any further data you may need to thrive in the dermatitis industry. This dermatitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Psoriasis refers to a skin condition that typically affects the knees, elbows, trunk, and scalp and results with a rash with itchy, scaly spots. The primary contributing factor may be an immune system issue wherein infection-fighting cells unintentionally kill healthy skin cells. The main classes of drugs in psoriasis are interleukin inhibitors, corticosteroids, anti-inflammatory, and tumor necrosis factor inhibitors. Corticosteroids are a group of steroid hormones generated by vertebrates' adrenal cortex and are also synthetic equivalents of these hormones. The different types of drugs include small molecules and biologics and involve various disease indications such as plaque psoriasis, nail psoriasis, guttate psoriasis, pustular psoriasis, and erythrodermic psoriasis. The several routes of administration include oral, topical, injectable, and distributed through hospitals, retail pharmacies, and e-commerce. The global psoriasis market is segmented - 1) By Drug class: Interleukin Inhibitors, Corticosteroids, Anti-Inflammatory, Tumor Necrosis Factor Inhibitor 2) By Distribution Channel: Hospitals, Retail Pharmacies, E-Commerce 3) By Drug Types: Small molecules, Biologics 4) By Route Of Administration: Oral, Tropical, Injectable 5) By Disease Indication: Plaque Psoriasis, Nail Psoriasis, Guttate Psoriasis, Pustular Psoriasis, Erythrodermic Psoriasis The global psoriasis market size will grow from $20.31 billion in 2022 to $22.80 billion in 2023 at a compound annual growth rate (CAGR) of 12.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global psoriasis is expected to grow to $34.50 billion in 2027 at a CAGR of 10.9%. The rise in the prevalence of psoriasis patients is driving the Psoriasis market. Psoriasis is caused due to immune system, genetics, and environment. The rise in psoriasis patients in the past few years can be mainly attributed to climate change, stress, and an unhealthy lifestyle. According to the World Psoriasis Day consortium, 125 million people globally - 2 to 3 percent of the total population have psoriasis. Therefore, the rise in the prevalence of psoriasis patients is expected to propel the growth of the psoriasis over forecast period. Major players in the psoriasis market are AbbVie Inc., Pfizer Inc., Novartis, Eli Lilly and Company, Celgene Corporation, Johnson & Johnson, Amgen Inc., Boehringer Ingelheim GmbH, Merck & Co Inc. and Janssen Biotech. The high cost of psoriasis therapy is expected to restrain the growth of the psoriasis market over the forecast period. For instance, according to a report published by WebMD, a US-based publication agency, disease-modifying antirheumatic medication (DMARD) used to treat PsA can cost between $1,500 and $2,000 per year. In the US, a dermatologist office visit typically costs $150 to $200. The high cost is because patent protections are preventing many alternative drugs. Therefore, the high cost of psoriasis therapy hampers the growth of the psoriasis market. Combination therapy is an emerging trend in the psoriasis market. Combination therapy is an f treatment that combines two different psoriasis treatments at the same time. When two drugs with different mechanisms of action are combined (combination therapy), the effect is greater than that obtained by monotherapy (treatment with a single drug). Studies suggest that combination therapy eases psoriasis symptoms more effectively than a single therapy and has lesser side effects. An example of combination therapy for the treatment of active psoriatic arthritis (PsA) is taltz (ixekizumab) with methotrexate developed by Eli Lilly and Company. The process of approval of psoriasis drugs is becoming easier globally. This is evident from the increasing approvals of drugs for psoriasis in recent years. Some of the examples include the first regulatory approval of SKYRIZI (risankizumab) for the treatment of plaque psoriasis in Japan, and the Center for Drug Evaluation and Research approved Avsola (infliximab-axxq) for the treatment of plaque psoriasis. Hence, the increasing ease of drug approvals is expected to drive the psoriasis drugs market in the forecast period. North America was the largest region in the psoriasis market in 2022. Middle East is expected to be the fastest-growing region in the global psoriasis market share during the forecast period. The regions covered in the global psoriasis market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the psoriasis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The psoriasis market consists of sales of Methotrexate, Ciclosporin, and Acitretin. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The psoriasis market research report is one of a series of new reports from The Business Research Company that provides psoriasis market statistics, including psoriasis industry global market size, regional shares, competitors with a psoriasis market share, detailed psoriasis market segments, market trends, and opportunities, and any further data you may need to thrive in the psoriasis industry. This psoriasis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Skin cancer drugs refer to chemotherapy drugs that are used to treat skin cancer. Skin cancer refers to aberrant skin cell proliferation, which most frequently appears on sun-exposed skin. However, this prevalent type of cancer can also develop on parts of your skin that are not often exposed to sunlight. Skin cancer can be of various types including actinic keratoses, basal cell carcinoma, squamous cell carcinoma, or melanoma. Examples of skin cancer drugs include 5-FU, Aldara, and Efudex. The main types of skin cancer drugs are actinic keratoses (AK), basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and melanoma. Actinic keratoses are broad, rough skin patches that can turn cancerous. It commonly appears on sun-exposed regions such as the face, scalp, backs of the hands, and chest. It is especially common in fair-skinned persons. Solar keratosis and senile keratosis are two terms for the same condition. The different classes of drugs include chemotherapy, immunotherapy, targeted agents and other drugs and are used in various sectors such as hospitals, cancer research centers, and clinics. The global skin cancer drugs market is segmented - 1) By Type: Actinic Keratoses (AK), Basal cell carcinoma (BCC), Squamous cell carcinoma (SCC), Melanoma 2) By End Users: Hospitals, Cancer Research Centers, Clinics 3) By Drug Class: Chemotherapy, Immunotherapy, Targeted Agents & Other Drugs The global skin cancer drugs market size will grow from $3.03 billion in 2022 to $3.41 billion in 2023 at a compound annual growth rate (CAGR) of 12.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global skin cancer drugs is expected to grow to $5.23 billion in 2027 at a CAGR of 11.3%. A significant rise in the prevalence of skin cancer is driving the demand for drugs for Skin Cancer. To treat such high cases of skin cancer, more new innovative skin cancer drugs are being manufactured.in 2022, according to The American Cancer Society, a US-based organization, approximately 99,780 new melanoma skin cancer is diagnosed and approximately 7,650 people are expected to die of melanoma skin cancer every year. This is boosting the demand for skin cancer drugs and thus driving the skin cancer drugs market. Major players in the skin cancer drugs market are Novartis AG, Bristol Myers Squibb, Eli Lilly, Meda, Sun Pharmaceutical Industries Ltd., Roche, Aqua Pharmaceuticals, Bausch Health, GlaxoSmithKline PLC, and Pfizer Inc. The increasing use of biologics and targeted therapies is acting as a restraint in the skin cancer drugs market. The targeted therapies drugs target melanoma cells only. The chemical drugs attack any fast-dividing cells while targeted therapies only attack the skin cancer-causing melanoma cells. Thus, doctors prefer targeted therapies to treat skin cancer. This is expected to affect the sales of conventional chemical skin cancer drugs and limit the growth of the skin cancer drugs market going forward. Companies in the Skin Cancer Market are increasingly looking for Strategic Alliances with other companies in the market. Strategic Alliance would help companies to enhance their R&D capability, expedite the development process of new drugs, and reinforce their competitive position in the market. For example, Leo Pharma has formed a strategic alliance with PellePharm, to develop a drug to treat a very rare form of skin cancer called Gorlin syndrome. MorphoSys and LEO Pharma strategically worked together to develop antibodies for the treatment of skin cancer. Pfizer had entered into a strategic alliance with Merck KGaA to manufacture an innovative drug for skin cancer. The European Medicines Agency (EMA) is the regulatory body that evaluates and supervises the production and sales of medicines for the safety and benefit of the customer, in the European Union Region. The manufacturers of skin cancer drugs and all other drugs need to comply with manufacturing practices specified by the EMA. EMA also regulates and supervises the drug quality, checking for the intended use of the drug and whether the drug is meeting the requirement of a clinical trial. EMA also educates the patients regarding the risks associated with taking skin cancer drugs such as Tafinlar and Opdivo, what are the safety measures that are needed to be taken while consuming the drug, the benefits of the drug, and all other relevant information about such drugs. In April 2022, Regeneron, a US-based biotechnology company acquired Checkmate Pharmaceuticals for $250 million. Through this acquisition, Regeneron expands its research efforts in immuno-oncology potential approaches for difficult-to-treat cancers. Checkmate Pharmaceuticals is a US-based company operating in skin cancer drugs. North America was the largest region in the skin cancer drugs market in 2022. Middle East is expected to be the fastest-growing region in the global skin cancer drugs market during the forecast period. The regions covered in the global skin cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the skin cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The skin cancer drugs market consists of sales of vismodegib (Erivedge) and sonidegib (Odomzo). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The skin cancer drugs market research report is one of a series of new reports from The Business Research Company that provides skin cancer drugs market statistics, including skin cancer drugs industry global market size, regional shares, competitors with a skin cancer drugs market share, detailed skin cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the skin cancer drugs industry. This skin cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cosmetic laser is a device used to reduce facial wrinkles and skin irregularities, such as acne scars or blemishes. Cosmetic lasers are also used for removing unwanted hair from the body by beaming highly concentrated light into the hair follicles. The main types of cosmetic lasers are standalone lasers, multiplatform lasers, and the models include pulsed dye laser (PDL), yttrium aluminum garnet (YAG) laser, carbon dioxide laser, erbium, intense pulsed light (IPL), radiofrequency, infrared, others. Standalone lasers have a single wavelength and a small variety of applicators used for treating a narrow range of indications. The multiplatform lasers use a handpiece with a small laser rod positioned inside having different wavelengths for a range of indications. The cosmetic laser is used by hospitals, skincare clinics, cosmetics surgical centers and is applied in various areas including hair removal, skin resurfacing, vascular lesions, scar and acne removal, body contouring, others. The global cosmetic lasers market is segmented - 1) By Type: Standalone Lasers, Multiplatform Lasers 2) By Modality: Pulsed Dye Laser (PDL), YAG Laser, Carbon Dioxide Laser, Erbium, Intense Pulsed Light (IPL), Radiofrequency, Infrared, Other Modalities 3) By Application: Hair Removal, Skin Resurfacing, Vascular Lesions, Scar and Acne Removal , Body Contouring, Other Applications 4) By End User: Hospitals, Skin care clinics, Cosmetics Surgical Centre The global cosmetic lasers market size grew from $2.42 billion in 2022 to $2.93 billion in 2023 at a compound annual growth rate (CAGR) of 21.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the cosmetic lasers is expected to grow to $5.89 billion in 2027 at a CAGR of 19.1%. Rising medical tourism supported the growth of the cosmetic lasers market over the historic period. The wide availability of better quality and low costs treatment options is increasing demand for medical tourism which provides better facilities and experienced doctors for better treatment and care, at an economical price. The rise in medical tourism, especially the cosmetic surgery medical tourism is likely to escalate the demand for cosmetic lasers. For instance, according to a 2021 report by Health Care Insider, a privately-owned company that helps consumers make better healthcare decisions, 290,000 Americans visited another nation in 2020 for medical procedures. In 2020, around 3% of Americans who travelled abroad did so for medical reasons. Therefore, the upraising medical tourism industry is predicted to augment the demand for cosmetic lasers market. Major players in the cosmetic lasers market are Cutera Inc., Cynosure Inc., Lumenis, Aerolase Corporation, ALMA LASERS Ltd., Sciton Inc., Syneron Candela, Solta Medical International Inc., ElEn SpA, Lynton Lasers Ltd., Medicure Group Of Companies, Thermage, ALLTEC GmbH (FOBA), Mentor, Fotona, Allergan Inc., and Galderma Laboratories LP. The stringent regulations for cosmetic laser products with respect to approval and marketing could is expected to be a restraint for the market in the forecast period. The laser device manufacturers must comply with a number of regulations relating to radiation safety, device efficiency and performance and other FDA guidelines on major hazard classes. The stringent regulatory processes and standards for cosmetic lasers delays the time required for the device to get to market which could act as a restraint in the forecast period. The companies are increasingly focusing on developing innovative and technologically advanced products to meet the requirement of end-users, expand the company product portfolio, and maximize company sales. For instance, in January 2020, Lumenis, an Israel-based manufacturer of minimally invasive clinical solutions for aesthetic, surgical, and ophthalmology markets launched LightSheer Quattro, a product that offers hair removal treatment for all skin types. In August 2020, Sensus Healthcare, Inc., a US-based medical device company specializing in highly effective, non-invasive, minimally invasive treatments, acquired Aesthetic Mobile Laser Services and Aesthetic Laser Partners for an undisclosed amount. Through this acquisition, Sensus Healthcare gets access to new dermatology accounts for its superficial radiation therapy (SRT) systems and an introduction to the new line of lasers. Aesthetic Mobile Laser Services and Aesthetic Laser Partners are Florida-based mobile aesthetic laser companies. North America was the largest region in the cosmetic lasers market in 2022. Asia-Pacific was the second largest market in cosmetic lasers market share. The regions covered in the cosmetic lasers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the cosmetic lasers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The cosmetic lasers market consists of sales of Alexandrite Lasers, Erbium Lasers, Pulsed Dye Lasers, and Nd:YAG Lasers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The cosmetic lasers market research report is one of a series of new reports from The Business Research Company that provides cosmetic lasers market statistics, including cosmetic lasers industry global market size, regional shares, competitors with a cosmetic lasers market share, detailed cosmetic lasers market segments, market trends and opportunities, and any further data you may need to thrive in the cosmetic lasers industry. This cosmetic lasers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The dermatology drugs market consists of sales of dermatology drugs by entities (organizations, sole traders and partnerships) that produce dermatology drugs to treat skin diseases. This industry includes establishments that produce drugs to treat diseases such as rosacea, dermatitis, hyperhidrosis, androgenic alopecia, acne drugs, microbial infections and other skin disorders. The main types of dermatology drugs are acne drugs, dermatitis, psoriasis, and other drugs for dermatology diseases. Psoriasis is a skin condition that causes red, itchy scaly patches on the knees, elbows, trunk, and scalp. Hypolipidemic drugs are a diverse class of medications used to treat high levels of fats (lipids) in the blood, such as cholesterol (hyperlipidemia). The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores, and others. The global dermatology drugs market size is expected to grow from $49.55 billion in 2021 to $54.54 billion in 2022 at a compound annual growth rate (CAGR) of 10.1%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The dermatology drugs market is expected to reach $117.82 billion in 2026 at a CAGR of 21.2%. The dermatology drugs market was mainly driven by rapid growth in emerging markets in the historic period. Emerging markets growth was aided by rising disposable income, stable political environment and increasing foreign investments in these countries. For instance, according to the IMF, China’s GDP growth rate was 2.3% in 2020. Additionally, according to the World Economic Outlook Reports by the IMF, the global growth is 6% in 2021 and expected to be 4.4% in 2022. Thus, strong economic growth boosted the demand for dermatology drugs and this drove the market during the historic period. High costs associated with drugs is a major issue faced by citizens of many countries. Pressure to contain costs and demonstrate value is widespread. Political uncertainty and persistent economic stress in numerous countries are calling into question the sustainability of public health care funding. In less wealthy countries, lack of cost-effective drugs has influenced the health conditions of the population and has led to a low average life expectancy. As a result, in countries such as Chad, Macedonia, Serbia, the pharmaceutical companies are faced with the pressure of reducing the price of drugs. The high costs associated with drugs are putting pressure on the revenues of dermatology drugs manufacturers. Drug manufacturing companies are using genome testing (genetic diagnosis) to reduce the time and costs spent in clinical trials. A clinical trial is a complex process and it often takes months for a drug to be available in the market. This deprives patients of cost-effective treatment. Researchers in the Rockefeller University used genomic testing and data analytics to predict the response of psoriasis patients for a given treatment. Genomic testing algorithms collect gene-expression data from skin biopsies and detect activity in 50,000 different genes. This technique can predict the response of a patient with an accuracy of 95% and within 12 weeks, thus saving significant time for clinical trials and the launch of new drugs. Major companies in the dermatology drugs market include Amgen, Reckitt Benckiser Group plc, AbbVie, Galderma S.A., LEO Pharma A/S, Bayer AG, GlaxosmithKline, Eli Lilly And Company, Novartis AG and Perrigo Company Plc. North America was the largest region in the dermatology drugs market in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the dermatology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the dermatology drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam. The global dermatology drugs market is segmented - 1) By Type: Acne Drugs, Dermatitis, Psoriasis, Other Drugs for Dermatology Diseases 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others 3) By Route of Administration: Oral, Parenteral, Others 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs